Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers - PubMed (original) (raw)
Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers
J Overgaard et al. Semin Radiat Oncol. 1996 Jan.
Abstract
It is now well established that most animal solid tumors contain oxygen-deficient hypoxic cells and that these cells will influence the response of those tumors to radiation. Identifying hypoxic cells in human tumors has proven more difficult, primarily because most of the direct procedures used in animals are not applicable to humans. However, substantial indirect evidence, which goes back to as early as 1909, clearly indicates the presence of hypoxia in human tumors, although with a considerable heterogeneity among individual tumors. Experimental studies during the last 30 years have shown that this source of radiation resistance can be effectively eliminated by a variety of procedures that include high oxygen-content gas breathing, nitrometric radiation sensitizers, blood transfusions, hemoglobin-oxygen affinity modifiers, and nicotinamide. A number of these procedures have also been tested clinically such that by 1995 over 10,000 patients in 83 randomized trials had undergone treatment designed to modify tumor hypoxia before radiation therapy. Although a number of these trials showed no benefit, an overview analysis showed that modification of tumor hypoxia significantly improved the locoregional tumor control after radiotherapy with an odds ratio of 1.21 (95% confidence interval 1.12-1.30). The treatment benefit could mostly be related to an improved response in head and neck with odds ratio 1.31 (1.19-1.43) and to a lesser extent in bladder tumors; no significant effect was observed in other tumor sites (cervix, lung and esophagus). Similar to the local control benefit, the overall survival rate improved with an overall odds ratio of 1.13 (1.05-1.21). The overall results thus showed that the biological issue related to hypoxia appears to be a sound rationale, which may impact the outcome of radiotherapy, especially with head and neck carcinoma. However, despite this wealth of positive data, "hypoxic modification" still has no impact on general clinical practice.
Similar articles
- Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
Overgaard J. Overgaard J. Oncol Res. 1994;6(10-11):509-18. Oncol Res. 1994. PMID: 7620219 - Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M, Van Esch G, Engels B, Verovski V, Storme G. De Ridder M, et al. Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Bull Cancer. 2008. PMID: 18390408 Review. - Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D, Brown JM. Vordermark D, et al. Strahlenther Onkol. 2003 Dec;179(12):801-11. doi: 10.1007/s00066-003-1150-9. Strahlenther Onkol. 2003. PMID: 14652668 Review. - [Radiation sensitizers: with special reference to hypoxic cell sensitizers].
Onoyama Y, Nakajima T, Tanaka M. Onoyama Y, et al. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):894-903. Gan To Kagaku Ryoho. 1986. PMID: 3963856 Japanese.
Cited by
- Vascular normalisation as the stepping stone into tumour microenvironment transformation.
Magnussen AL, Mills IG. Magnussen AL, et al. Br J Cancer. 2021 Aug;125(3):324-336. doi: 10.1038/s41416-021-01330-z. Epub 2021 Apr 7. Br J Cancer. 2021. PMID: 33828258 Free PMC article. Review. - New paradigms and future challenges in radiation oncology: an update of biological targets and technology.
Liauw SL, Connell PP, Weichselbaum RR. Liauw SL, et al. Sci Transl Med. 2013 Feb 20;5(173):173sr2. doi: 10.1126/scitranslmed.3005148. Sci Transl Med. 2013. PMID: 23427246 Free PMC article. - Hypoxia imaging-directed radiation treatment planning.
Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Rajendran JG, et al. Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:44-53. doi: 10.1007/s00259-006-0135-1. Eur J Nucl Med Mol Imaging. 2006. PMID: 16763816 Review. - GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.
Hoskin PJ, Sibtain A, Daley FM, Wilson GD. Hoskin PJ, et al. Br J Cancer. 2003 Oct 6;89(7):1290-7. doi: 10.1038/sj.bjc.6601260. Br J Cancer. 2003. PMID: 14520462 Free PMC article. - DNA Repair Deficient Chinese Hamster Ovary Cells Exhibiting Differential Sensitivity to Charged Particle Radiation under Aerobic and Hypoxic Conditions.
Cartwright IM, Su C, Haskins JS, Salinas VA, Sunada S, Yu H, Uesaka M, Hirakawa H, Chen DJ, Fujimori A, Kato TA. Cartwright IM, et al. Int J Mol Sci. 2018 Jul 30;19(8):2228. doi: 10.3390/ijms19082228. Int J Mol Sci. 2018. PMID: 30061540 Free PMC article.
LinkOut - more resources
Full Text Sources
Other Literature Sources